Wall Street’s Moderna downgrade is the most interesting call because it highlights a lesson investors often overlook: great fundamentals do not automatically mean a great stock at any price.

Moderna’s business may improve, its pipeline may deliver, and earnings expectations may recover — yet if the share price has already priced in too much future success, the risk/reward can deteriorate quickly.

That is why analyst upgrades and downgrades should be read as valuation signals, not simple buy-or-sell instructions.

Netflix and Target show how improving expectations can create upside, while Moderna shows the opposite: sometimes the biggest risk isn't a bad company — it's paying too much for a good story.

For me, this is the key takeaway from last week’s analyst moves: fundamentals tell you what a company could become; valuation tells you how much of that future you are already paying for.

@WallStreet_Tiger [哟哟]